![Adaptive Manufacturing:-The new flexibility in medical device assembly Adaptive Manufacturing:-The new flexibility in medical device assembly](https://cdn.magzter.com/1394808148/1730438393/articles/yaK-Ejyca1730517091974/ADAPTIVE-MANUFACTURINGTHE-NEW-FLEXIBILITY-IN-MEDICAL-DEVICE-ASSEMBLY.jpg)
For manufacturers to succeed in the industry and meet the increasing expectations of the marketplace, they must be apprised of developments. Medical device manufacturing is a sophisticated, iterative process that involves multiple crucial stages. It commences with the ideation and conceptualization phase, where manufacturing and medical expertise are crucial. As they convert innovative medical concepts or procedures into workable and functional goods; engineers, scientists, and healthcare professionals must work closely together throughout this phase. In all these human errors cannot be neglected and to assure an error free process, usage of automation and adaptive practices helps to curb out any errors in the process. This flexibility and precision help manufacturers innovate and manufacture sustainably.
Challenges and possibilities
هذه القصة مأخوذة من طبعة November 2024 من Express Pharma.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة November 2024 من Express Pharma.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
![Pharma's strategic path to growth in the nutra maze Pharma's strategic path to growth in the nutra maze](https://reseuro.magzter.com/100x125/articles/5843/1981257/S7RL7urj51738585009245/PHARMAS-STRATEGIC-PATH-TO-GROWTH-IN-THE-NUTRA-MAZE.jpg)
Pharma's strategic path to growth in the nutra maze
The nutraceutical market is a thriving ecosystem of opportunities. For pharma companies, it's a space where the allure of a $11.55 billion pie by 2030 is tempered by a maze of regulatory grey zones, stiff competition, and trust-eroding marketing practices.
![PRIME NEO from Gandhi Automations PRIME NEO from Gandhi Automations](https://reseuro.magzter.com/100x125/articles/5843/1981257/pSoWQPTC11738587385901/PRIME-NEO-FROM-GANDHI-AUTOMATIONS.jpg)
PRIME NEO from Gandhi Automations
Gandhi Automation's PRIME NEO High Speed Doors are designed to provide superior sealing and resistance to pressure differences for clean rooms. And the added advantage is that it is absolutely washable
![AI smart camera for real-time automation AI smart camera for real-time automation](https://reseuro.magzter.com/100x125/articles/5843/1981257/s351jeUlb1738587298023/AI-SMART-CAMERA-FOR-REALTIME-AUTOMATION.jpg)
AI smart camera for real-time automation
Integrated asset management functionality and a deep learning tool for training and evaluation keep productivity high and costs low
![PROSOLV® 730: Directly compressible carrier for lipophilic ingredients PROSOLV® 730: Directly compressible carrier for lipophilic ingredients](https://reseuro.magzter.com/100x125/articles/5843/1981257/6cppB9bi11738586297726/PROSOLV-730-DIRECTLY-COMPRESSIBLE-CARRIER-FOR-LIPOPHILIC-INGREDIENTS.jpg)
PROSOLV® 730: Directly compressible carrier for lipophilic ingredients
Nearly 90% of molecules in the discovery pipeline and 40% of drugs with market approval are poorly water soluble.
![Complete environmental monitoring solution - testo Saveris Pharma Complete environmental monitoring solution - testo Saveris Pharma](https://reseuro.magzter.com/100x125/articles/5843/1981257/TqM5z0Frt1738587594040/COMPLETE-ENVIRONMENTAL-MONITORING-SOLUTION-TESTO-SAVERIS-PHARMA.jpg)
Complete environmental monitoring solution - testo Saveris Pharma
testo Saveris Pharma monitors and documents temperature, humidity, differential pressure, and other parameters without interruption and compliantly with GxP so that audits and inspections are conducted smoothly
![The unmissable Asia healthcare opportunity The unmissable Asia healthcare opportunity](https://reseuro.magzter.com/100x125/articles/5843/1981257/FkJMEHrta1738583001800/THE-UNMISSABLE-ASIA-HEALTHCARE-OPPORTUNITY.jpg)
The unmissable Asia healthcare opportunity
BCG's latest report, The Unmissable Asia Healthcare Opportunity, highlights the region's $5 trillion healthcare market potential by 2030, driven by demographic shifts, investment, and innovation.
![2025: Healthcare and Lifesciences investment outlook 2025: Healthcare and Lifesciences investment outlook](https://reseuro.magzter.com/100x125/articles/5843/1981257/gni4wTlSk1738585367741/2025-HEALTHCARE-AND-LIFESCIENCES-INVESTMENT-OUTLOOK.jpg)
2025: Healthcare and Lifesciences investment outlook
Kapil Khandelwal, Managing Partner, Toro Finserve and EquNev Capital, interprets the possibilities for the various segments of the Indian lifesciences and healthcare sector for this year
![The group's offerings range from over a billion injection doses annually to bespoke medical machinery The group's offerings range from over a billion injection doses annually to bespoke medical machinery](https://reseuro.magzter.com/100x125/articles/5843/1981257/ytLU7DSi51738579961377/THE-GROUPS-OFFERINGS-RANGE-FROM-OVER-A-BILLION-INJECTION-DOSES-ANNUALLY-TO-BESPOKE-MEDICAL-MACHINERY.jpg)
The group's offerings range from over a billion injection doses annually to bespoke medical machinery
Rishad Dadachanji, MD, Dadachanji Group speaks on the company's evolution from a pharma packaging company to a diversified solutions provider in biotechnology, automation, and sterile processing.
![DECODING THE M&A LANDSCAPE DECODING THE M&A LANDSCAPE](https://reseuro.magzter.com/100x125/articles/5843/1981257/m9-U1Nic21738580242970/DECODING-THE-MA-LANDSCAPE.jpg)
DECODING THE M&A LANDSCAPE
Consolidation has emerged as a major trend as the pharma industry seeks new avenues of growth and looks to expand its existing capabilities.
![Evolution and commercialisation of cell and gene therapies Evolution and commercialisation of cell and gene therapies](https://reseuro.magzter.com/100x125/articles/5843/1981257/6TatCW-851738582670742/EVOLUTION-AND-COMMERCIALISATION-OF-CELL-AND-GENE-THERAPIES.jpg)
Evolution and commercialisation of cell and gene therapies
Satyen Sanghavi, Founder & CSO, Regrow Biosciences traces the evolution of cell and gene therapies, highlighting global milestones, industry growth, and reimbursement models.